

**CENTOGENE N.V., Am Strande 7, 18055 Rostock, Germany**

U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549  
United States

March 31, 2022

**Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act**

Ladies and Gentlemen,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Centogene N.V. made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission on March 30, 2022. The disclosure can be found under the heading “Miscellaneous— Disclosure under Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRA)” in the Annual Report on Form 20-F.

Respectfully submitted,

/s/ Kim Stratton

\_\_\_\_\_  
Kim Stratton  
Chief Executive Officer  
Centogene N.V.

**CENTOGENE N.V.**  
Am Strande 7

18055 Rostock, Germany

Tel: +49 (0)381 80 113 - 400  
Fax: +49 (0)381 80 113 - 401  
Email: [info@centogene.com](mailto:info@centogene.com)  
[www.centogene.com](http://www.centogene.com)

**Management Board:**  
Kim Stratton (CEO)

René Just (CFO)

Dr. Volkmar Weckesser (CIO)

**Supervisory Board:**  
Peer Schatz (Chairman)

**Statutory seat:**

Amsterdam, registered with the Kamer van Koophandel (Netherlands) under 72822872

**Bank account details:**

Bank: Commerzbank AG  
IBAN: DE60130400000108866500  
BIC: COBADEFFXXX

---

---